Full Name
CHNG WEE JOO
Variants
Chng W.J
Chng, W.J.
Chng W.-J.
Chng, Wee Joo
Chng, W.-J.
 
 
 
Email
mdccwj@nus.edu.sg
 
Other emails
 

Publications

Results 1-20 of 81 (Search time: 0.021 seconds).

Issue DateTitleAuthor(s)
12018A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphataseZhou, J ; Toh, S.H.-M; Chan, Z.-L; Quah, J.Y; Chooi, J.-Y ; Tan, T.Z ; Chong, P.S.Y ; Zeng, Q ; Chng, W.-J 
220-Sep-2018Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosisTeoh, Phaik Ju ; An, Omer ; Chung, Tae-Hoon ; Chooi, Jing Yuan ; Toh, Sabrina HM ; Fan, Shuangyi ; Wang, Wilson ; Koh, Bryan TH; Fullwood, Melissa J ; Ooi, Melissa G ; de Mel, Sanjay; Soekojo, Cinnie Y; Chen, Leilei ; Ng, Siok Bian ; Yang, Henry ; Chng, Wee Joo 
32016Aberrant localization of apoptosis protease activating factor-1 in lipid raft sub-domains of diffuse large B cell lymphomasHirpara, J.L ; Loh, T ; Ng, S.B ; Chng, W.J ; Pervaiz, S 
42015Aberrant nuclear factor-kappa B activity in acute myeloid Leukemia: From molecular pathogenesis to therapeutic targetZhou J. ; Ching Y.Q. ; Chng W.-J. 
528-Apr-2014Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study GroupTse, E.; Chan, T.S.Y.; Koh, L.-P.; Chng, W.-J. ; Kim, W.-S.; Tang, T.; Lim, S.-T.; Lie, A.K.W.; Kwong, Y.-L.
628-Mar-2013ATM-dependent spontaneous regression of early Eμ-myc-induced murine B-cell leukemia depends on natural killer and T cells.Croxford, J.L. ; Tang, M.L.; Pan, M.F. ; Huang, C.W.; Kamran, N.; Phua, C.M.; Chng, W.J. ; Ng, S.B. ; Raulet, D.H.; Gasser, S. 
7Jul-2017Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinomaKong, L.R ; Tan, T.Z ; Ong, W.R; Bi, C; Huynh, H ; Lee, S.C ; Chng, W.J ; Eichhorn, P.J.A ; Goh, B.C 
811-Jul-2018BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemiaZhou Y.; Zhou J. ; Lu X.; Tan T.-Z. ; Chng W.-J. 
917-Mar-2017Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age SubgroupHeinz Ludwig; Meletios A. Dimopoulos; Philippe Moreau; Wee Joo Chng ; Hartmut Goldschmidt; Roman Hajek; Thierry Facon; Ludek Pour; Ruben Niesvizky; Albert Oriol; Laura Rosinol; Aleksandr Suvorov; Gianluca Gaidano; Tomas Pika; Katja Weisel; Vesselina Goranova-Marinova; Antonio Palumbo; Heidi Gillenwater; Nehal Mohamed; Sanjay Aggarwal; Shibao Feng; Douglas Joshua
1022-Sep-2017Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR StudyHartmut Goldschmidt; Philippe Moreau; Heinz Ludwig; Ruben Niesvizky; Wee Joo Chng ; Douglas Joshua; Katja Weisel; Andrew Spencer; Robert Orlowski; Shibao Feng; Karim Iskander; Meletios A. Dimopoulos
112018Celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myelomaShanmugam, M.K ; Ahn, K.S; Lee, J.H; Kannaiyan, R; Mustafa, N ; Manu, K.A ; Siveen, K.S ; Sethi, G ; Chng, W.J ; Kumar, A.P 
12Oct-2009Centrosomes and myeloma; aneuploidy and proliferationChng, W.J. ; Fonseca, R.
132008Clinical and biological significance of RAS mutations in multiple myelomaChng, W.J. ; Van, Wier S.; Fonseca, R.; Gonzalez-Paz, N.; Price-Troska, T.; Rajkumar, S.V.; Kyle, R.A.; Henderson, K.J.; Greipp, P.; Jacobus, S.; Oken, M.M.; Van, Ness B.
142014Clinical profiles of multiple myeloma in asia-an asian myeloma network studyKim, K.; Lee, J.H.; Kim, J.S.; Min, C.K.; Yoon, S.S.; Shimizu, K.; Chou, T.; Kosugi, H.; Suzuki, K.; Chen, W.; Hou, J.; Lu, J.; Huang, X.-J.; Huang, S.-Y.; Chng, W.J. ; Tan, D.; Teoh, G.; Chim, C.S.; Nawarawong, W.; Siritanaratkul, N.; Durie, B.G.
152010Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: Identification of 1p31-32 deletion as a prognostic factor in myelomaChng, W.J. ; Van, Wier S.; Keats, J.J.; Bergsagel, P.L.; Fonseca, R.; Gertz, M.A.; Chung, T.-H. ; Baker, A.; Carpten, J.
16Apr-2012Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivoChan, D.; Tyner, J.W.; Chng, W.J. ; Bi, C.; Okamoto, R.; Said, J.; Ngan, B.D.; Braunstein, G.D.; Koeffler, H.P. 
172009Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AMLZhou, J. ; Bi, C.; Janakakumara, J.V. ; Liu, S.-C.; Chng, W.-J. ; Tay, K.-G. ; Poon, L.-F. ; Xie, Z. ; Palaniyandi, S. ; Chen, C.-S. ; Yu, H. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
182016Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: A role for MARCKS in acquired resistance to proteasome inhibitorsFranke, N.E; Kaspers, G.L; Assaraf, Y.G; Meerloo, J; Niewerth, D; Kessler, F.L; Poddighe, P.J; Kole, J; Smeets, S.J; Ylstra, B; Bi, C; Chng, W.J ; Horton, T.M; Menezes, R.X; Musters, R.J.P; Zweegman, S; Jansen, G; Cloos, J
1916-Nov-2013Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: Analysis of clinical features and outcomes from the Asia Lymphoma study groupKim, S.J.; Jung, H.A.; Chuang, S.-S.; Hong, H.; Guo, C.-C.; Cao, J.; Hong, X.-N.; Suzuki, R.; Kang, H.J.; Won, J.H.; Chng, W.-J. ; Kwong, Y.-L.; Suh, C.; Song, Y.-Q.; Zhu, J.; Tay, K.; Lim, S.T.; Suzumiya, J.; Lin, T.-Y.; Kim, W.S.
202015Functional characterization of D9, a novel deazaneplanocin a (DZNep) analog, in targeting acute myeloid leukemia (AML)Jiang, Xia; Lim, Cheryl Zi Hui; Li, Zhimei; Lee, Puayleng; Yatim, Siti Maryam J. M.; Guan, Peiyong; Li, Juntao; Zhou, Jianbiao ; Pan, Jingxuan; Chng, Wee Joo ; Chai, Li Lin Christina ; Yu, Qiang